Supplyside West

Booth 7425
 
Novozymes, an ingredient supplier specializing in probiotics, enzymes, and other bioactives, will showcase emerging evidence supporting the health and wellness applications of two of its ingredients at its booth, as well as on the Supplier Presentation Theater Stage. The company will also be hosting a happy hour at its booth on October 26^th, from 3:00-4:00 p.m.
 
ProbioBrain
 
The company will feature ProbioBrain, which is a probiotic strain called Bifidobacterium longum 1714, during the week. The ingredient has been evidenced in two placebo-controlled clinical trials to potentially benefit adults’ psychological and physical responses to everyday stress including cortisol output, and modulate brain activity associated with a calm state of mind and emotional balance.
 
The market for supplements with brain health benefits is poised to reach $4 billion by 2025, at a CAGR of 7.2%, Novozymes reported, citing Grand View Research. According to Novozymes’ own consumer research, sleep and stress issues are the most challenging aspects of mental wellness, with older generations reporting more trouble with sleep, and younger generations more likely to report work-related stress undermining their quality of life. Across all groups, multiple tactics are used to cope, and there is a high acceptance rate when it comes to using dietary supplements to support mental wellness.
 
On Wednesday, October 25, at the Supplier Presentation Theater, company representative Veronique Rufin-Soumine will present “Psychobiotics: The emergence of game-changing evidence for the future of mental wellness.”
 
Experts at Novozymes will be on hand during the event to discuss emerging insights into psychobiotics, which is a relatively new term describing probiotic bacteria linked to cognitive and mental health.
 
PyloPass
 
Novozymes will also be showcasing Limosilactobacillus reuteri DSM 17648, a postbiotic product branded as Pylopass which is linked to reductions in the load of Helicobacter pylori in the stomach. H. pylori is found in about 50% of the world’s population, and is linked to gastric upset.
 
Based on the evidence supporting PyloPass, structure-function claims for the ingredient can include: decrease in gastric inflammation; reductio of side effects associated with antibiotic treatment; reduction of gastro-intestinal symptoms in H. pylori positive subjects; and change in intestinal microbiota composition.
 
On Thursday, October 26^th, from 12:00-12:20 p.m. at the Supplier Presentation Theater, Mikkel Jungersen, global head of medical affairs, will give a presentation called “Are postbiotics the solution to the H. pylori challenge?”
 
Jungersen will introduce the role of H. pylori and discuss the challenges associated with it. Clinical studies on H. pylori and the health benefits of strain-specific postbiotics will be presented, with an outlook on what the future could look like for the human microbiome.
 
MenaquinGold
 
Novozymes is also featuring MenaquinGold, its brandsed vitamin K2 as MK-7, which is a non-soy and non-synthetic vitamin K2 derived from a chickpea-based, soy-free fermentation process. The ingredient, which is suitable for a variety of supplement formats, is supportive of bone and heart health, with emerging evidence suggesting its potential for nerve health and sports nutrition applications.